Literature DB >> 12445823

Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats.

Qi Cao1, Ki M Mak, Charles S Lieber.   

Abstract

We previously reported that dilinoleoylphosphatidylcholine (DLPC) decreases lipopolysaccharide-induced TNF-alpha generation by Kupffer cells of ethanol-fed rats by blocking p38, ERK1/2, and NF-kappaB activation. Here we show that DLPC also decreases TNF-alpha induction by acetaldehyde, a toxic metabolite released by ethanol oxidation. Acetaldehyde induces TNF-alpha generation with a maximal effect at 200 microM and activates p38 and ERK1/2; the latter in turn activates NF-kappaB. This effect is augmented in Kupffer cells of ethanol-fed rats, with upregulation of cytochrome P4502E1 by ethanol. DLPC decreases TNF-alpha generation by blocking p38, ERK1/2, and NF-kappaB activation. Likewise, SB203580, which abolishes p38 activation, and PD098059, which abrogates ERK1/2 and NF-kappaB activation, diminish TNF-alpha generation. Since increased TNF-alpha generation plays a pathogenic role in alcoholic liver disease, the DLPC action on Kupffer cells may explain, in part, its beneficial effects on liver cell injury after ethanol consumption.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445823     DOI: 10.1016/s0006-291x(02)02672-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat.

Authors:  Martin J Ronis; Soheila Korourian; Michael L Blackburn; Jamie Badeaux; Thomas M Badger
Journal:  Alcohol       Date:  2010-01-29       Impact factor: 2.405

Review 2.  Treatment of alcoholic liver disease.

Authors:  Ina Bergheim; Craig J McClain; Gavin E Arteel
Journal:  Dig Dis       Date:  2005       Impact factor: 2.404

3.  Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis.

Authors:  Núria Tarrats; Anna Moles; Albert Morales; Carmen García-Ruiz; José C Fernández-Checa; Montserrat Marí
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

4.  Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines.

Authors:  Zheng Shen; Joanne M Ajmo; Christopher Q Rogers; Xiaomei Liang; Lisa Le; Michel M Murr; Yanhua Peng; Min You
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

5.  FR167653 attenuates murine immunological liver injury.

Authors:  Hong-Wei Yao; Jun Li; Ji-Qiang Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

6.  Protective effect of phosphatidylcholine on restoration of ethanol-injured hepatocytes related with caveolin-1.

Authors:  Yuan Zhang; Wei Zou; Fenggong Cui; Nan Wang; Dongyan Zhang; Yuying Cui; Peng Liu; Jing Liu
Journal:  J Membr Biol       Date:  2013-11-29       Impact factor: 1.843

7.  Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.

Authors:  Wataru Okiyama; Naoki Tanaka; Tamie Nakajima; Eiji Tanaka; Kendo Kiyosawa; Frank J Gonzalez; Toshifumi Aoyama
Journal:  J Hepatol       Date:  2009-04-02       Impact factor: 25.083

Review 8.  Signaling mechanisms in alcoholic liver injury: role of transcription factors, kinases and heat shock proteins.

Authors:  Pranoti Mandrekar
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

9.  Ethanol inhibits LPS-induced signaling and modulates cytokine production in peritoneal macrophages in vivo in a model for binge drinking.

Authors:  Stephen B Pruett; Ruping Fan
Journal:  BMC Immunol       Date:  2009-09-18       Impact factor: 3.615

10.  Peroxisome proliferator-activated receptor and retinoic x receptor in alcoholic liver disease.

Authors:  Tommaso Mello; Simone Polvani; Andrea Galli
Journal:  PPAR Res       Date:  2009-09-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.